



1F12

Patent Application  
Attorney Docket No. PC10228B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Farzan Rastinejad

APPLICATION NO.: 09/863,976

Examiner: Delacroix Muirhei, Cybille

FILING DATE: May 23, 2001

Group Art Unit: 1614

TITLE: METHODS AND COMPOSITIONS FOR  
RESTORING CONFORMATIONAL  
STABILITY OF A PROTEIN OF THE P53  
FAMILY

Commissioner for Patents  
Washington, D.C. 20231


Sir:

In the Official Action of June 3, 2004, the Examiner noted that numerous references cited on Applicant's Forms 1449 were no longer to be found in the file of the immediate parent application. Applicant hereby provides duplicate copies of the Forms 1449 affected by this situation, and copies of all of the missing references except for 2 Chemical Abstracts citations and a reference book which will be promptly ordered and copied.

The Examiner is welcome to contact the undersigned if any further assistance is needed in this regard.

Respectfully submitted,

Date: December 13, 2004

  
\_\_\_\_\_  
E. Victor Donahue  
Attorney for Applicant(s)  
Reg. No. 35,492

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212)733 -2739



# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. PC10228B

SERIAL NO. 09/863,976

APPLICANT FARZAN RASTINEJAD, et al.


FILING DATE May 23, 2001

GROUP 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCL ASS	FILING DATE IF APPROPRIATE
		5	9	0	0	3	6	0	5/4/99	Welch, et al.			
		6	2	7	0	9	5	4	8/7/2001	Welch, et al.			
		6	3	5	9	0	0	0	3/19/2002	Jiang, et al.			
		6	3	7	2	7	8	5	4/16/02	Huang			
		6	3	8	4	0	4	9	5/7/02	Camden			
		6	3	8	7	6	7	3	5/14/02	Evans, et al.			
		6	3	8	7	9	0	3	5/14/02	Dinsmore, et al.			
		6	3	8	8	1	3	1	5/14/02	Medina, et al.			
		6	3	9	1	8	8	8	5/21/02	Gleich			
		6	3	9	1	3	0	2	5/21/02	Wallace, et al.			
		6	3	9	1	9	1	3	5/21/02	Pagé, et al.			
		6	3	9	1	8	5	3	5/21/02	Greene, et al.			
		6	3	9	1	9	1	6	5/21/02	Dal, et al.			
		6	3	9	2	0	6	3	5/21/02	Ali, et al.			
		6	3	9	5	7	2	9	5/28/02	Ferzaz, et al.			
		6	3	9	5	7	4	9	5/28/02	Li, et al.			
		6	3	9	5	7	7	1	5/28/02	Ramados, et al.			
		6	3	9	9	5	8	3	6/4/02	Ylihonko, et al.			
		6	3	9	9	5	9	8	6/4/02	Pikul, et al.			
		6	3	9	9	6	3	8	6/4/02	Vite, et al.			
		6	3	9	9	6	5	3	6/4/02	Henke			
		6	3	9	9	6	4	7	6/4/02	Kalgutkar, et al.			
		6	4	0	3	5	5	4	6/11/02	Strelchenok, et al.			
		6	4	0	3	5	6	9	6/11/02	Achterrath			
		6	4	0	3	5	9	2	6/11/02	Howard			
		6	4	0	3	6	2	5	6/11/02	Nagao, et al.			
		6	4	0	6	6	9	9	6/18/02	Wood			
		6	4	1	0	0	2	9	6/25/02	Mukhopadhyay, et al			

[illegible]



# FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
WO	0	2	2	4	6	9	2		3/28/02	WO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			"Strategies For Manipulation the p53 pathway in treatment of human cancer" T.R. Hupp, et al. Biochem J. (2000), 352, pgs 1-17
			"Restoration of the tumor suppressor function to mutant p53...." V. Bykov, et al. Nature Medicine, Vol. 8, No. 3, March 2002
			"P53 and IGFBP-3: Apoptosis and Cancer Protection" A. Grimberg, Molecular Genetics & Metabolism. 70, pgs 85-89, 2000
			"New Insights into p53 Regulation & Gene Therapy for Cancer" Alain G. Zelmet, et al. Biochemical Pharmacology, Vol 60, pp 1153-1163, 2000
			"Lucilactaene, a New Cell Inhibitor in p53-Transfected Cancer Cells" Riken, et al., Journal of Antibiotics, Vol. 54, No. 10, pp. 850-854, Oct. 2001,
			"Pharmaceutical Rescue of Mutant p53 Conformation & Function" Barbara Foster, et al. Science, Vol. 286, 12/24/99, pp2507-2510
			"Crystal Structure of a p53 Tumor Suppressor-DNA Complex...", Yunje Cho, et al., Science, Vol. 265, 7/15/94, pp 346-355
			"The Emerging p53 Gene Family" William G. Kaelin, Jr., Jour. National Cancer Inst., Vol. 91, No. 7, 4/7/99, pp594-598
			"Chemotherapeutic Targeting of p53", Martin L. Smith, et al, Cancer Biology & Therapy, Vol. 1, pp1,2, 2001
			"Rescuing the Function of Mutant p53" Alex N. Bullock, et al., Nature Reviews-Cancer, Vol.1, Oct. 2001, pp68-76
			"Oncogenic Mutations of the p53 Tumor Suppressor: "...A. Sigal, et al., Cancer Research, 60, 6788-6793, 12/15/2000
			"The Effects of wild-type p53 tumor suppressor activity..." C. Cadwell, et al. Gene 277 (2001) pp 15-30

EXAMINER

DATE CONSIDERED

Jerome Goldberg

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p align="center"><b>INFORMATION DISCLOSURE CITATION</b></p> <p align="center"><i>(Use several sheets if necessary)</i></p>		<p>ATTY. DOCKET NO. PC10228B</p>	<p>SERIAL NO. Express Mail No. EL446402284US</p>
<p>APPLICANT Farzan Rastinejad et al.</p>		<p>FILING DATE May 23, 2001</p>	
		<p>GROUP 1624 (anticipated)</p>	
		<p>William Wilson, et al., "Hypoxia-Selective Antitumor Agents. 2. Electronic Effects of 4-Substituents on the Mechanisms of Cytotoxicity and Metabolic Stability of Nitracrine Derivatives"; <i>J. Med. Chem.</i>, vol. 32, pp. 31-38 (1989)</p>	
		<p>T.R. Hupp, "Regulation of p53 Protein Function Through Alterations In Protein-Folding Pathways"; <i>Cell. Mol. Life Sci.</i>, vol. 55 pp. 88-95 (1999)</p>	
		<p>K. Sakagami et al., Chemical Abstracts, vol. 24, No. 25, June 17, 1996, Abstract No. 332043</p>	
		<p><del>M. Wuonola et al., Chemical Abstracts, vol. 128, 1998, Abstract No. 175800</del></p>	
		<p><del>M. Wuonola et al., Chemical Abstracts, vol. 128, No. 14, April 6, 1998, Abstract No. 162631</del></p>	
		<p>T. Ohnishi, et al., "Restoration of Mutant TP53 to Normal TP53 Function by Glycerol as a Chemical Chaperone", <i>Radiation Research</i>, vol. 151, no. 4 pp. 498-500 (1999)</p>	
<p>EXAMINER</p>		<p>DATE CONSIDERED</p>	
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

USERS\DOCS\LA21952\LPEVD\3K%G01\\_.DOC / 166984

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.